

CONFIDENTIAL

COLARIS AP®
APC and MYH Analysis Result

PHYSICIAN	SPECIMEN	PATIENT
John Smith, MD Comprehensive Medical Center 1100 Grand Ave Away, GA 12345	Specimen: Blood Draw date: Aug 01, 2010 Accession date: Aug 02, 2010 Report Date: Aug 12, 2010	Name: Doe, Jane Date of Birth: April 1, 1492 Patient ID: 000000 Gender: Female Accession #: 00000000-BLD Requisition #: 000000

Test Results and Interpretation

NO MUTATION DETECTED

<u>Test Performed:</u> <i>APC</i> sequencing comprehensive rearrangement	<u>Result:</u> No Mutation Detected No Mutation Detected	<u>Interpretation:</u> No Mutation Detected No Mutation Detected
<i>MYH</i> sequencing comprehensive rearrangement	No Mutation Detected No Mutation Detected	No Mutation Detected No Mutation Detected

Analysis consists of sequencing of all exons and immediately adjacent intronic regions of the APC and MYH genes and large rearrangement testing of the APC and MYH genes by microarray comparative genomic hybridization (microarray CGH). The classification and interpretation of all variants identified in this assay reflects the current state of scientific understanding at the time this report was issued. In some instances, the classification and interpretation of such variants may change as new scientific information becomes available.

No deleterious mutation was found in APC or MYH by full sequence analysis and large rearrangement testing. Sequence analysis identifies mutations in all 15 exons and approximately 440 adjacent non-coding base pairs of APC and in all 16 exons and approximately 450 adjacent intronic base pairs of MYH. Microarray CGH identifies duplications and deletions involving one or more exons of APC and MYH. While there are unusual abnormalities that this test will not detect, this result rules out the majority of mutations responsible for Familial Adenomatous Polyposis (FAP) and MYH-Associated Polyposis (MAP). If this individual has never had a diagnosis of colorectal polyposis and/or cancer, it is recommended that testing an affected relative be considered to help clarify the clinical significance of this negative test result.

Please contact Myriad Professional Support at 1-800-469-7423 to discuss any questions regarding this result.

Director Name Here
Qualifications Here

Director Name Here
Qualifications Here

These test results should only be used in conjunction with the patient's clinical history and any previous analysis of appropriate family members. It is strongly recommended that these test results be communicated to the patient in a setting that includes appropriate counseling. The accompanying Technical Specifications summary describes the analysis, method, performance characteristics, nomenclature, and interpretive criteria of this test. This test may be considered investigational by some states. This test and its performance characteristics were determined by Myriad Genetic Laboratories. It has not been reviewed by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary.